Navigation Links
Keryx Reports Results of Open Label Extension Study Examining Long-Term Use of Zerenex, an Iron-Based Phosphate Binder, for the Treatment of Hyperphosphatemia
Date:9/23/2009

NEW YORK, Sept. 23 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced results of the Open Label Extension (OLE) trial of Zerenex (ferric citrate) for the treatment of elevated serum phosphorous levels, or hyperphosphatemia, in patients with end-stage renal disease (ESRD) on dialysis. The OLE trial, conducted in Taiwan, enrolled 29 of the 37 Taiwanese patients that had completed the randomized, multi-center, multi-national (United States and Taiwan) dose-ranging Phase 2 study. This OLE represents the first trial to examine the long-term safety and efficacy of Zerenex as a phosphate binder. The treatment period in all previous Zerenex Phase 2 clinical trials did not exceed 28 days.

The OLE trial provided for a daily dose, ranging from 2 to 6 g/day of Zerenex, for a period of up to one year following completion of the 28-day, dose-ranging Phase 2 study. The average duration of the patients' participation in the OLE trial was 306 +/- 85 days.

Data from the OLE trial indicate that the mean serum phosphorus level throughout the trial was 5.22 +/- 0.18 mg/dL, and the mean product of calcium times phosphate (CaxP) was 49.06 +/- 2.15 mg(2)/dL(2), both within the normal range as recommended by the KDOQI guidelines. In addition, during the OLE trial, the administration of IV iron as a supplement was withheld in 8 patients (27.6%) for periods ranging from 3 to 6 months and the administration of EPO was withheld in 8 patients (27.6%) for short periods because the hemoglobin, hematocrit, and iron parameters were within normal clinical ranges as assessed by the investigator. There were no signs of potential iron overload in the study patients, and there were no Zerenex-related serious adverse events as noted by either the pati
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
2. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
3. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
4. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
5. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
6. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
7. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
8. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
9. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
10. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
11. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... LAS VEGAS , July 25, 2014 GrowBLOX ... of a binding Memorandum of Understanding ("MOU") with LaurelCo, LLC, ... to pursue the acquisition of both cultivation and dispensary medical ... . Pursuant to the MOU, GBLX will acquire a 20% ... use our proprietary GrowBLOX TM growing chambers, as well ...
(Date:7/25/2014)...  Acsis Inc., the market leader for supply ... recently posted an article, "Future of Running ... needs for companies, extended supply chain, and explains ... no longer work today.  The article explains how ... mobile technology, machine to machine (M2M) connectivity, and ...
(Date:7/25/2014)... MEXICO CITY , July 25, 2014 ... a Latin American healthcare sciences publisher, launched a library ... on conditions such as cancer and heart disease. Healthcare ... most up-to-date information to deliver better patient care. ... rapidly, with many relying on smartphones and tablets to ...
Breaking Medicine Technology:GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 2GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 3Acsis Addresses Questions on the Modern Supply Chain 2Healthcare Sciences Publisher PLM and IBM Speed Access to Medical Information to Deliver Better Patient Care with Mobile 2Healthcare Sciences Publisher PLM and IBM Speed Access to Medical Information to Deliver Better Patient Care with Mobile 3Healthcare Sciences Publisher PLM and IBM Speed Access to Medical Information to Deliver Better Patient Care with Mobile 4
... UTRECHT, the Netherlands , July 8, 2010 ... therapeutics for cancer, announces the,establishment of its Scientific Advisory Board (SAB). The ... on the unique,functions of its proprietary miRNAs. , ... The SAB is chaired by ...
... , July 8, 2010 According to a new ... India and China ) Patient,Monitoring Market (2010 - ... devices,market is expected to be worth US$3,075 million by ... nearly 62.9% of the total revenues. The BRIC,patient monitoring market is ...
Cached Medicine Technology:InteRNA Technologies Announces Establishment of Scientific Advisory Board 2InteRNA Technologies Announces Establishment of Scientific Advisory Board 3New Report Patient Monitoring Emerging Markets (BRIC - Brazil, Russia, India and China) 2010 - 2014 Published by MarketsandMarkets 2New Report Patient Monitoring Emerging Markets (BRIC - Brazil, Russia, India and China) 2010 - 2014 Published by MarketsandMarkets 3
(Date:7/25/2014)... (PRWEB) July 25, 2014 The American ... new volunteer network “ABTA CommYOUnity™” during its annual patient ... pivotal time for the brain tumor community as we ... patient and caregiver support services and funding brain tumor ... are passionate about brain tumor awareness and getting our ...
(Date:7/25/2014)... IL (PRWEB) July 25, 2014 There are ... and 500 diagnosed each day. Though when someone hears the ... confused and are unsure of the next step and where ... helping people figure out that next step by providing and ... this more than Brian Olson, member of the ABTA’s Board ...
(Date:7/25/2014)... Progress in understanding the molecular genetics of ... promising brain tumor treatments, according to Patrick Wen, MD, ... Center for Neuro-Oncology, Dana-Farber Cancer Institute. , At the ... Conference in Chicago, July 25-26, Dr. Wen will moderate ... impacting the development of new treatments and advancing strategies ...
(Date:7/25/2014)... According to the new report "Sapphire Technology Market by ... Analysis & Forecast to 2013 - 2020", the global ... Billion by 2020 at a CAGR of 12.31%, whereas ... to reach $6.17 billion by 2020 at a CAGR ... and geography. , Browse more than 65 market data ...
(Date:7/25/2014)... CA (PRWEB) July 25, 2014 Splashtop, ... WorkPlace Partner Program . Splashtop Business and Splashtop Enterprise ... and will leverage the MaaS360 WorkPlace SDK to ... , Splashtop Business and Splashtop Enterprise offer secure remote ... device. High performance, ease of use, collaborative ...
Breaking Medicine News(10 mins):Health News:American Brain Tumor Association Unveils Brand Identity for Newly Launched Volunteer Network 2Health News:American Brain Tumor Association Unveils Brand Identity for Newly Launched Volunteer Network 3Health News:American Brain Tumor Association Board of Directors Member Shares Story of Brain Tumor Survivorship 2Health News:American Brain Tumor Association Board of Directors Member Shares Story of Brain Tumor Survivorship 3Health News:Immunotherapy, Targeted Molecular Therapies Among Promising New Treatments for Brain Tumors 2Health News:Immunotherapy, Targeted Molecular Therapies Among Promising New Treatments for Brain Tumors 3Health News:Immunotherapy, Targeted Molecular Therapies Among Promising New Treatments for Brain Tumors 4Health News:Sapphire Technology Market Estimated to Reach $3.01 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Sapphire Technology Market Estimated to Reach $3.01 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Sapphire Technology Market Estimated to Reach $3.01 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Sapphire Technology Market Estimated to Reach $3.01 Billion by 2020 – New Report by MarketsandMarkets 5Health News:Sapphire Technology Market Estimated to Reach $3.01 Billion by 2020 – New Report by MarketsandMarkets 6Health News:Splashtop Joins the MaaS360 WorkPlace Partner Program 2Health News:Splashtop Joins the MaaS360 WorkPlace Partner Program 3Health News:Splashtop Joins the MaaS360 WorkPlace Partner Program 4
... With audience members cheering and,famous Chicago chefs watching ... for the finalists at Consorta,s Battle of the Hospital,Chefs. ... the organic cucumbers he,serves the patients at Saint Mary,s ... event,s Gold Chef Award, becoming the reigning champion of,chefs ...
... systemic fibrosis (NSF) is a newly identified debilitating and ... is characterized by a thickening and hardening of the ... it can also affect internal organs and can progress ... within a few weeks. Although it is not clear ...
... and problems in ones neighborhood are associated with greater ... in Vancouver, Canada. , Social environment has long been ... in youth, but few studies have empirically tested social ... their implications for childhood asthma. , Edith Chen, Ph.D., ...
... PHOENIX, Sept. 27 Matrixx Initiatives, Inc.,(Nasdaq: ... and,markets products that provide consumers with "Better Ways ... 3, 2007, at the,William Blair & Company Small-Cap ... presenting at 3:20 p.m. ET. To listen to ...
... for the pub musicians who play them, Irish researchers say ... is not only salve for the lungs, it is music to ... air quality in Irish pubs as well as the health of ... play them, research suggests. , "Research to date looking at ...
... Non Media types, its,hard not to notice that Britney has been ... something is definitely going on with our,Famed Star. On a ... makeover and when asked what type of smile she wanted, she ... celebrity stars and right,on top of that pile was ... you ...
Cached Medicine News:Health News:National Battle of the Hospital Chefs Cooks Up a Winner 2Health News:Higher death rates in kidney patients with newly recognized disease 2Health News:Higher death rates in kidney patients with newly recognized disease 3Health News:Dysfunctional families and bad neighborhoods may worsen asthma in children and adolescents 2Health News:Dysfunctional families and bad neighborhoods may worsen asthma in children and adolescents 3Health News:Matrixx Initiatives, Inc. to Present at the William Blair & Company Small-Cap Growth Stock Conference 2Health News:Accordions Breathe Easier Since Smoking Ban 2
... (WxDxH): 31.1 x 13.6 x 15.3 cm, ... x 20.5 cm, Capacity: 4 - 50 ... 35 mm bottles, 4 - 150 x ... x 80 mm bottle, Power Requirements: 230V ...
... ,Smaller slot surface area results in increased ... ,Small slot dimensions require less sample than dot-blotters. ... signal generated with the slot-blotter allows you to ... all types of transfer membranes ,Allows ...
... Temperature controlled oven containing a rotisserie or ... of Northern, Southern and Western blots. May ... staining. Use of bottle hybridizations allows minimal ... sensitivity and reduced reagent costs. Acrylic/polycarbonate door ...
... system consists of four basic components: sample well ... clamping plate (see diagram). The sample well plate ... dots, or slots (see below). All three plates ... accessory plate in conjunction with a complete system. ...
Medicine Products: